Stock News

Vuzix (VUZI) Reaches $7.35 After 6.00% Up Move; Tesaro, Inc. (TSRO) Had 15 Analysts Last Week

Vuzix Corporation (NASDAQ:VUZI) Logo

The stock of Vuzix Corporation (NASDAQ:VUZI) is a huge mover today! The stock increased 3.52% or $0.25 during the last trading session, reaching $7.35. About 686,955 shares traded or 58.29% up from the average. Vuzix Corporation (NASDAQ:VUZI) has risen 1.72% since June 17, 2017 and is uptrending. It has underperformed by 10.85% the S&P500. Some Historical VUZI News: ; 20/03/2018 – Glancy Prongay & Murray LLP Announces Investigation on Behalf of Vuzix Corporation Investors (VUZI); 06/04/2018 – VUZIX CORP – CO IS SEEKING DAMAGES IN EXCESS OF $80 MLN; 23/04/2018 – DJ Vuzix Corporation, Inst Holders, 1Q 2018 (VUZI); 20/03/2018 – Vuzix Discloses 10 New Leading Technology Companies Evaluating its Waveguide Optics; 30/05/2018 – VUZIX PARTNERS WITH QUALCOMM ON THE NEW SNAPDRAGON XR1 PLATFORM TO DEVELOP NEXT GENERATION AR SMART GLASSES; 12/03/2018 – VUZIX – BEGINS MASS PRODUCTION OF WINDOWS-BASED SMART GLASSES FOR TOSHIBA; FIRST PRODUCTION SHIPMENTS EXPECTED TO BE DELIVERED WITHIN ABOUT 30 DAYS; 12/03/2018 Vuzix Begins Mass Production of the World’s First Windows-based Smart Glasses for Toshiba; 06/04/2018 – VUZIX CORP – HAS FILED A DEFAMATION LAWSUIT AGAINST RICARDO ANTONIO PEARSON IN SUPREME COURT OF STATE OF NEW YORK, COUNTY OF NEW YORK; 10/04/2018 – Vuzix M300 Smart Glasses Selected by Oracle as Part of Service Cloud Showcase at ModernCX; 21/03/2018 – Bragar Eagel & Squire, P.C. is Investigating Vuzix Corporation (VUZI) on Behalf of Stockholders and Encourages Investors to Contact the FirmThe move comes after 7 months positive chart setup for the $201.61M company. It was reported on Jun, 17 by Barchart.com. We have $7.79 PT which if reached, will make NASDAQ:VUZI worth $12.10M more.

Among 25 analysts covering Tesaro Inc (NASDAQ:TSRO), 15 have Buy rating, 1 Sell and 9 Hold. Therefore 60% are positive. Tesaro Inc had 81 analyst reports since August 24, 2015 according to SRatingsIntel. Credit Suisse maintained the stock with “Outperform” rating in Friday, May 4 report. Raymond James initiated the stock with “Strong-Buy” rating in Tuesday, September 1 report. Bank of America initiated it with “Neutral” rating and $97 target in Tuesday, August 30 report. As per Wednesday, January 3, the company rating was maintained by Guggenheim. As per Thursday, March 17, the company rating was initiated by Citigroup. Morgan Stanley initiated the shares of TSRO in report on Friday, January 13 with “Overweight” rating. On Monday, October 10 the stock rating was maintained by Leerink Swann with “Outperform”. The firm has “Equal-Weight” rating by Barclays Capital given on Wednesday, February 28. On Thursday, July 27 the stock rating was maintained by Cowen & Co with “Hold”. The firm earned “Buy” rating on Tuesday, August 8 by Oppenheimer. See Tesaro, Inc. (NASDAQ:TSRO) latest ratings:

31/05/2018 Broker: Citigroup Rating: Buy New Target: $100.0000 Maintain
07/05/2018 Broker: Lake Street Rating: Buy New Target: $80.0000 Maintain
04/05/2018 Broker: Bank of America Old Rating: Buy New Rating: Buy Old Target: $94 New Target: $88 Maintain
04/05/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Outperform Old Target: $141 New Target: $128 Maintain
04/05/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $102 New Target: $100 Maintain
04/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $104.0000 Maintain
02/05/2018 Broker: Argus Research Old Rating: Buy New Rating: Buy Old Target: $154 New Target: $110 Maintain
16/04/2018 Broker: Piper Jaffray Rating: Hold Maintain
27/03/2018 Broker: Wedbush Rating: Buy New Target: $76.0000 Maintain
28/02/2018 Broker: Cowen & Co Rating: Hold New Target: $66.0 Maintain

Since December 19, 2017, it had 3 insider buys, and 0 sales for $73,990 activity. $30,495 worth of stock was bought by Russell Grant on Thursday, March 22. Boris Paul A bought $23,555 worth of stock. Travers Paul J had bought 3,252 shares worth $19,940.

Among 5 analysts covering Vuzix (NASDAQ:VUZI), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vuzix had 17 analyst reports since August 17, 2015 according to SRatingsIntel. The rating was maintained by Maxim Group with “Buy” on Wednesday, September 6. The stock has “Buy” rating by Chardan Capital Markets on Monday, September 28. The firm has “Buy” rating by Maxim Group given on Friday, October 28. The stock of Vuzix Corporation (NASDAQ:VUZI) earned “Buy” rating by Chardan Capital Markets on Monday, December 14. Chardan Capital Markets maintained Vuzix Corporation (NASDAQ:VUZI) on Monday, January 8 with “Buy” rating. The company was maintained on Friday, November 10 by Maxim Group. The firm has “Buy” rating given on Monday, August 17 by Chardan Capital Markets. The stock of Vuzix Corporation (NASDAQ:VUZI) has “Buy” rating given on Monday, June 26 by Maxim Group. Maxim Group maintained Vuzix Corporation (NASDAQ:VUZI) on Wednesday, July 19 with “Buy” rating. The firm earned “Buy” rating on Thursday, December 10 by Rodman & Renshaw.

Vuzix Corporation designs, manufactures, markets, and sells wearable display devices in the United States and internationally. The company has market cap of $201.61 million. The companyÂ’s products are worn like eyeglasses that enable the user to view video and digital content, such as movies, computer data, the Internet, or video games. It currently has negative earnings. The Company’s products include binocular wearable displays that contain two micro displays mounted in a frame attached to eyeglass-style temples or stereo headphones; monocular smart glasses products for the enterprise, industrial, and commercial markets, as well as video headphones; augmented reality products, which provide the user a live, direct or indirect, view of a physical, and real-world environment; and video viewing glasses as mobile displays for entertainment and gaming for on-the-go users, as well as support for stepping into virtual worlds, simulations, and virtual reality gaming.

Investors sentiment increased to 3.56 in 2018 Q1. Its up 0.56, from 3 in 2017Q4. It is positive, as 6 investors sold Vuzix Corporation shares while 3 reduced holdings. 15 funds opened positions while 17 raised stakes. 6.35 million shares or 208.08% more from 2.06 million shares in 2017Q4 were reported. Valley Natl Advisers Inc invested in 0% or 1,731 shares. Qci Asset Inc Ny has invested 0% in Vuzix Corporation (NASDAQ:VUZI). Vanguard Group reported 933,293 shares or 0% of all its holdings. Granite Inv Prtnrs Limited reported 0.02% of its portfolio in Vuzix Corporation (NASDAQ:VUZI). Goldman Sachs Group reported 130,027 shares. Bancshares Of New York Mellon has 0% invested in Vuzix Corporation (NASDAQ:VUZI). Tower Rech Capital Lc (Trc) has invested 0% in Vuzix Corporation (NASDAQ:VUZI). Millennium Mngmt Lc owns 181,167 shares. Cambridge Invest Research Advsrs reported 15,250 shares. State Street Corp accumulated 21,812 shares or 0% of the stock. Winslow Evans And Crocker Inc reported 1,500 shares stake. Assetmark invested in 0% or 250 shares. Citadel Advisors Limited Liability has invested 0% of its portfolio in Vuzix Corporation (NASDAQ:VUZI). Atlantic Lc has 10,000 shares. Bluecrest Capital holds 0.02% in Vuzix Corporation (NASDAQ:VUZI) or 132,166 shares.

More important recent Vuzix Corporation (NASDAQ:VUZI) news were published by: Nasdaq.com which released: “9 Augmented Reality Stocks to Enhance Your Portfolio” on June 06, 2018, also Prnewswire.com published article titled: “Vuzix Appoints Vice President of Operations and Vice President of Engineering”, Prnewswire.com published: “Vuzix to Webcast Annual Shareholder Meeting on June 13” on June 13, 2018. More interesting news about Vuzix Corporation (NASDAQ:VUZI) was released by: Prnewswire.com and their article: “Vuzix Launches the Vuzix Blade® Smart Glasses Developer Center” with publication date: June 12, 2018.

Since March 1, 2018, it had 9 insider purchases, and 8 insider sales for $60.88 million activity. The insider Viswanathan Ravi bought 145,532 shares worth $8.35 million. Huber Martin H. Jr. also sold $98,913 worth of Tesaro, Inc. (NASDAQ:TSRO) shares. The insider MOULDER LEON O JR bought $284,640. Another trade for 1,809 shares valued at $99,224 was sold by Bogle Grant C.. PEARSON TIMOTHY R sold $141,265 worth of stock. 145,532 shares were bought by BASKETT FOREST, worth $8.35M on Friday, March 2. NEW ENTERPRISE ASSOCIATES 13 LP had bought 116,445 shares worth $6.68 million.

The stock decreased 4.01% or $1.66 during the last trading session, reaching $39.77. About 2.08M shares traded or 49.04% up from the average. Tesaro, Inc. (NASDAQ:TSRO) has declined 66.21% since June 17, 2017 and is downtrending. It has underperformed by 78.78% the S&P500. Some Historical TSRO News: ; 06/04/2018 – CLOVIS WINS FDA APPROVAL FOR EXPANDED USE OF RUBRACA; 08/05/2018 – MERCK – EMA APPROVED LYNPARZA TABLETS (300 MG TWICE DAILY) FOR USE AS A MAINTENANCE THERAPY WITH PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER; 03/04/2018 – ASTRAZENECA PLC – EUROPEAN MEDICINES AGENCY ACCEPTS REGULATORY SUBMISSION FOR LYNPARZA IN BRCA-MUTATED, HER2-NEGATIVE METASTATIC; 08/05/2018 – OncoSec Expands Relationship with Merck, Announces Clinical Collaboration to Evaluate Combination of lmmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer; 06/04/2018 – CLOVIS ONCOLOGY-IN ADDITION TO GRANTING RUBRACA APPROVAL FDA CONVERTED APPROVAL OF INITIAL TREATMENT INDICATION FROM ACCELERATED TO REGULAR APPROVAL; 02/04/2018 – MYRIAD GENETICS INC – ASTRAZENECA AND MERCK ARE SEEKING APPROVAL OF LYNPARZA IN JAPAN FOR TREATING PATIENTS WITH BRCA-MUTATED METASTATIC BREAST CANCER; 23/05/2018 – MERCK & CO – SUBMITTED SBLA FOR KEYTRUDA IN COMBINATION TO U.S. FDA AND NEW DATA WILL BE SHARED WITH AGENCY; 10/04/2018 – Oncolytics Biotech(R) Presents Positive REOLYSIN(R) Data in Combination with Keytruda and anti-CD73 at International Oncolytic Virus Conference 2018; 09/04/2018 – KEYTRUDA® (pembrolizumab) Monotherapy Met Primary Endpoint in Phase 3 KEYNOTE-042 Study, Significantly Improving OS as First; 16/04/2018 – Dynavax Reports Interim Data for SD-101 in Combination With KEYTRUDA(R) (pembrolizumab) in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck

Investors sentiment increased to 1.14 in 2018 Q1. Its up 0.13, from 1.01 in 2017Q4. It increased, as 41 investors sold Tesaro, Inc. shares while 58 reduced holdings. 33 funds opened positions while 80 raised stakes. 60.57 million shares or 4.53% more from 57.95 million shares in 2017Q4 were reported. Commerzbank Aktiengesellschaft Fi has invested 0% of its portfolio in Tesaro, Inc. (NASDAQ:TSRO). Price T Rowe Incorporated Md has 0.03% invested in Tesaro, Inc. (NASDAQ:TSRO). Renaissance Technologies Ltd Llc owns 186,500 shares or 0.01% of their US portfolio. Gabelli Funds holds 0.01% or 14,900 shares. Rhumbline Advisers holds 37,902 shares or 0% of its portfolio. Bailard stated it has 0.03% in Tesaro, Inc. (NASDAQ:TSRO). Financial Bank Of New York Mellon Corporation holds 622,767 shares. Jennison Lc accumulated 0.02% or 389,585 shares. Exane Derivatives holds 2,441 shares. Pnc Financial Service Inc stated it has 0% in Tesaro, Inc. (NASDAQ:TSRO). New Jersey-based Jacobs Levy Equity Management Inc has invested 0% in Tesaro, Inc. (NASDAQ:TSRO). Iguana Healthcare Mgmt Limited Com has invested 1.69% in Tesaro, Inc. (NASDAQ:TSRO). Westpac Banking accumulated 4,156 shares. Wellington Mngmt Grp Llp accumulated 0.1% or 7.57M shares. Asset One Co Limited holds 57,335 shares or 0.01% of its portfolio.

Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. The company has market cap of $2.18 billion. It markets Rolapitant, a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting under the VARUBI brand name. It currently has negative earnings. The firm is also developing Niraparib, an orally active and potent poly polymerase inhibitor, which is in various clinical trials to treat ovarian or breast cancers.

More recent Tesaro, Inc. (NASDAQ:TSRO) news were published by: Seekingalpha.com which released: “Reader Inquiry: Has Tesaro Finally Found A Bottom?” on May 23, 2018. Also Seekingalpha.com published the news titled: “Tesaro: Can Upcoming Catalyst Bring Fortune To This Unpopular Company?” on June 01, 2018. Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid …” with publication date: June 15, 2018 was also an interesting one.

Vuzix Corporation (NASDAQ:VUZI) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *